In Vivo - Strategic Analysis For Medtech And Pharma Leaders since 1981
Podcasts
In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company’s monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications.
Innovation
AI and machine learning can help companies push failures further up to avoid costly late-stage disappointments.
Overseeing the diverse EMEA region as the regional president of Johnson & Johnson’s Vision business has been a whirlwind of activity for Jacqueline Henderson, in her role since 2023. Fresh back from the ESCRS 2024 meeting, she spoke to In Vivo about how J&J responds to market needs.
Leadership
Market Access
As the US biosimilars market approaches the end of its first decade, it has seen another busy year, with Amgen’s surprise launch of a rival to Eylea shaking up expectations as other first-time approvals rolled in throughout 2024. Meanwhile, competition to Stelara is waiting in the wings from the start of 2025.